Brief: Krystal Biotech Announces Clinical Data On Topical Application Of B-VEC
24/04/2023 12:27
April 24 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES CLINICAL DATA ON TOPICAL
APPLICATION
OF B-VEC TO THE EYE TO TREAT OCULAR COMPLICATIONS IN A PATIENT
WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA UNDER A COMPASSIONATE USE
PROGRAM
* KRYSTAL BIOTECH INC - TOPICAL APPLICATION OF B-VEC TO EYE
WAS
WELL TOLERATED
* KRYSTAL BIOTECH- PATIENT SHOWED SIGNIFICANT IMPROVEMENT OF
VISUAL ACUITY AND COMPLETE CORNEAL RE-EPITHELIZATION IN TOPICAL
APPLICATION OF B-VEC TO EYE
Source text for Eikon: ID:nGNX1Tmg8B
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion